-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Financial Survey: ImmunoGen (NASDAQ:IMGN) Versus CohBar (NASDAQ:CWBR)
Financial Survey: ImmunoGen (NASDAQ:IMGN) Versus CohBar (NASDAQ:CWBR)
ImmunoGen (NASDAQ:IMGN – Get Rating) and CohBar (NASDAQ:CWBR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Earnings and Valuation
This table compares ImmunoGen and CohBar's top-line revenue, earnings per share and valuation.
Get ImmunoGen alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ImmunoGen | $69.86 million | 17.19 | -$139.30 million | ($0.69) | -7.88 |
CohBar | N/A | N/A | -$15.48 million | ($0.16) | -0.94 |
CohBar has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than CohBar, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ImmunoGen and CohBar's net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
ImmunoGen | -179.64% | -67.02% | -37.22% |
CohBar | N/A | -58.66% | -54.72% |
Risk & Volatility
ImmunoGen has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, CohBar has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for ImmunoGen and CohBar, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ImmunoGen | 0 | 2 | 3 | 0 | 2.60 |
CohBar | 0 | 0 | 1 | 0 | 3.00 |
ImmunoGen presently has a consensus target price of $9.80, suggesting a potential upside of 80.15%. CohBar has a consensus target price of $2.50, suggesting a potential upside of 1,566.67%. Given CohBar's stronger consensus rating and higher probable upside, analysts plainly believe CohBar is more favorable than ImmunoGen.
Insider & Institutional Ownership
95.6% of ImmunoGen shares are owned by institutional investors. Comparatively, 7.9% of CohBar shares are owned by institutional investors. 3.3% of ImmunoGen shares are owned by company insiders. Comparatively, 6.5% of CohBar shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
CohBar beats ImmunoGen on 9 of the 13 factors compared between the two stocks.
About ImmunoGen
(Get Rating)
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
About CohBar
(Get Rating)
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
ImmunoGen (NASDAQ:IMGN – Get Rating) and CohBar (NASDAQ:CWBR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
免疫基因(納斯達克:IMGN-GET評級)和CohBar(納斯達克:CWBR-GET評級)都是小盤醫療公司,但哪種投資更好?我們將根據這兩家公司的風險、股息、盈利能力、收益、分析師建議、機構所有權和估值等方面的實力進行比較。
Earnings and Valuation
收益和估值
This table compares ImmunoGen and CohBar's top-line revenue, earnings per share and valuation.
這張表格比較了免疫基因和CohBar的營收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
ImmunoGen | $69.86 million | 17.19 | -$139.30 million | ($0.69) | -7.88 |
CohBar | N/A | N/A | -$15.48 million | ($0.16) | -0.94 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
免疫基因 | 6,986萬美元 | 17.19 | -1.393億美元 | ($0.69) | -7.88 |
Cohbar | 不適用 | 不適用 | -1,548萬美元 | ($0.16) | -0.94 |
CohBar has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than CohBar, indicating that it is currently the more affordable of the two stocks.
CohBar的收入較低,但收益高於免疫基因。免疫系統目前的市盈率低於CohBar,這表明它目前是兩隻股票中價格更實惠的一隻。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
ImmunoGen | -179.64% | -67.02% | -37.22% |
CohBar | N/A | -58.66% | -54.72% |
淨利潤率 | 股本回報率 | 資產回報率 | |
免疫基因 | -179.64% | -67.02% | -37.22% |
Cohbar | 不適用 | -58.66% | -54.72% |
Risk & Volatility
風險與波動性
ImmunoGen has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, CohBar has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
ImmunoGen的貝塔係數為0.9,這意味着其股價的波動性比標準普爾500指數低10%。相比之下,CohBar的貝塔係數為2.22,這意味着其股價的波動性比標準普爾500指數高122%。
Analyst Recommendations
分析師建議
This is a summary of recent ratings and price targets for ImmunoGen and CohBar, as reported by MarketBeat.
據MarketBeat報道,這是免疫基因和CohBar最近評級和目標價的摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
ImmunoGen | 0 | 2 | 3 | 0 | 2.60 |
CohBar | 0 | 0 | 1 | 0 | 3.00 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
免疫基因 | 0 | 2 | 3 | 0 | 2.60 |
Cohbar | 0 | 0 | 1 | 0 | 3.00 |
ImmunoGen presently has a consensus target price of $9.80, suggesting a potential upside of 80.15%. CohBar has a consensus target price of $2.50, suggesting a potential upside of 1,566.67%. Given CohBar's stronger consensus rating and higher probable upside, analysts plainly believe CohBar is more favorable than ImmunoGen.
ImmunoGen目前的共識目標價為9.80美元,暗示潛在上行空間為80.15%。CohBar的共識目標價為2.50美元,暗示潛在上漲1,566.67%。考慮到CohBar更高的共識評級和更高的可能上行空間,分析師顯然認為CohBar比ImmunoGen更有利。
Insider & Institutional Ownership
內部人與機構所有權
95.6% of ImmunoGen shares are owned by institutional investors. Comparatively, 7.9% of CohBar shares are owned by institutional investors. 3.3% of ImmunoGen shares are owned by company insiders. Comparatively, 6.5% of CohBar shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
免疫基因公司95.6%的股份由機構投資者持有。相比之下,CohBar 7.9%的股份由機構投資者持有。免疫系統3.3%的股份由公司內部人士持有。相比之下,CohBar 6.5%的股份由公司內部人士持有。強大的機構持股表明,捐贈基金、對衝基金和大型基金管理公司相信,一隻股票的長期表現將好於大盤。
Summary
摘要
CohBar beats ImmunoGen on 9 of the 13 factors compared between the two stocks.
CohBar在比較兩隻股票的13個因素中有9個超過了免疫基因。
About ImmunoGen
關於免疫基因
(Get Rating)
(獲取評級)
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
免疫基因公司是一家臨牀階段的生物技術公司,開發抗體-藥物結合(ADC)療法來治療癌症。該公司的候選產品包括針對葉酸受體α(FRA)的ADC Mirvetuximab soravtansine,它正處於治療對鉑耐藥的卵巢癌的第三階段臨牀試驗;以及Pivekimab Sunirine,一種針對CD123的ADC,正處於治療急性髓系白血病和原始漿細胞樣樹突狀細胞腫瘤的第二階段臨牀試驗。它的臨牀前計劃包括IMGC936,這是與MacroGenics公司共同開發的ADC;以及IMGN151,是一種針對FRA的候選產品。該公司與羅氏公司、安進/牛津生物治療公司、拜耳保健股份公司、禮來公司、諾華生物醫學研究所公司、CytomX治療公司、Fusion製藥公司、Debiamm International SA公司和MacroGenics公司合作。免疫基因公司成立於1980年,總部設在馬薩諸塞州的沃爾瑟姆。
About CohBar
關於CohBar
(Get Rating)
(獲取評級)
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
CohBar,Inc.是一家臨牀階段生物技術公司,專注於基於線粒體的療法(MBTS)的研究和開發,用於治療慢性和與年齡相關的疾病。該公司開發MBTS用於治療非酒精性脂肪性肝炎(NASH)、肥胖症、脂肪肝、特發性肺纖維化、2型糖尿病、急性呼吸窘迫綜合徵、癌症和阿爾茨海默病等心血管疾病。它的主要臨牀候選藥物是CB4211,一種新型的精製MOTS-c線粒體衍生肽類似物,正處於治療NASH和肥胖症的Ia/Ib期臨牀試驗的Ib期階段。該公司的臨牀前計劃包括用於纖維化疾病的CB5138類似物,以及用於新冠肺炎相關ARDS的CB5064類似物。CohBar,Inc.成立於2007年,總部設在加利福尼亞州門洛帕克。
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對免疫系統及相關公司評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧